APA (7th ed.) Citation

SH, L., K, G., CS, S., Y, M., A, L., & N, P. (2022). Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. PharmacoEconomics, 40(Suppl 1), 91. https://doi.org/10.1007/s40273-021-01092-9

Chicago Style (17th ed.) Citation

SH, Lo, Gorni K, Sutherland CS, Martí Y, Lloyd A, and Paracha N. "Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom." PharmacoEconomics 40, no. Suppl 1 (2022): 91. https://doi.org/10.1007/s40273-021-01092-9.

MLA (9th ed.) Citation

SH, Lo, et al. "Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom." PharmacoEconomics, vol. 40, no. Suppl 1, 2022, p. 91, https://doi.org/10.1007/s40273-021-01092-9.